China's CanSinoBIO's inhaled COVID booster reported stronger against BA.1 Omicron subvariant than Sinovac shot

CanSinoBIO's inhaled COVID booster stronger against BA.1 Omicron subvariant than Sinovac shot Chinese vaccine firm CanSino Biologic's inhalation-based candidate elicited a better antibody response as a booster against the BA.1 Omicron sub-variant than Sinovac's shot, but the antibody level dropped in months, clinical trial data showed. Reuters Reuters

...

The result came as top political leaders in China called for proper tracking of virus mutation and developing of new vaccines and treatments in the country's effort to refine its COVID control strategy. read more

...